Intec Pharma gets $750,000 grant for Parkison’s research

Intec Pharma has developed a new delivery method for Levodopa, the leading treatment for Parkison's disease.

April 16, 2013 22:09
A RENDERING of the inaugurated Edmond and Lily Safra Center for Brain Sciences at the Hebrew U

brain research center 370. (photo credit: Hebrew University)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Intec Pharma Ltd. has obtained a $750,000 grant from the Michael J Fox Foundation for Parkinson’s research. Intec Pharma has developed a new delivery method for Levodopa, the leading treatment for the disease.

Levodopa is effective but does not last long in the bloodstream, and it must therefore be given in large doses, resulting in side effects. Intec Pharma’s accordion capsule releases the drug gradually, extending its effectiveness and lowering the dosage. The company successfully conducted a phase-2 clinical trial of the drug and is seeking a partner to commercialize it.

The Michael J Fox Foundation makes grants of up to $1 million a year. Two other Israeli companies have previously received grants: Neuroderm Ltd., which has received two grants; and Proneuron Biotechnologies, which has gone out of business.

Intec Pharma’s share price fell 0.4 percent to NIS 1.36 on Sunday, giving it a market cap of NIS 292m.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection